In Germany, the authorities are going to introduce a new protein-based COVID-19 vaccine by the end of this week. As per the information provided by the sources, around 1.4m doses of Nuvaxovid is going to deliver in the country this week as the European Union has given the support.
Moreover, the Nuvaxovid vaccine has been created by the US biotech company Novavax, and they are going to reach Germany in this current week.
Last Friday, the nation’s health minister, Karl Lauterbach, gave the confirmation. More than a million doses will arrive as the German government’s maximum order by the year 2022 has been amounted to 34m doses.
Along with this, the products that have been developed has only been used in Indonesia and the Philippines, but it was approved for use in the European Union in the previous December.
Additionally, the mRNA vaccines produced by Pfizer/BioNTech and Moderna or viral vector made by AstraZeneca and Johnson & Johnson, Nuvaxovid is a protein-based vaccine.
All of the vaccines include a non-infectious element on the surface of the Sars-CoV-2 virus, which generates a protective immune response when the body’s immune cells come into contact with it.
The last June, Novavax has made the declaration that the vaccines that are developed under them are proven to be more effective, over 90 percent against all of the symptomatic infections with the Alpha variant, in trials including almost 30,000 volunteers in the United States and Mexico.